MAKO Surgical Corp. Stockholders Approve Merger With Stryker Corporation

MAKO Surgical Corp. (Nasdaq:MAKO) ("MAKO") announced that MAKO stockholders voted at a special meeting of stockholders held today to approve the adoption of the Agreement and Plan of Merger (the "Merger Agreement") providing for the merger of MAKO with and into a wholly owned subsidiary of Stryker Corporation (NYSE:SYK). Based on a tabulation of the stockholder vote, approximately 99% of all votes cast, which represents approximately 65% of all outstanding shares on November 12, 2013, the record date for the special meeting, were voted in favor of the merger. MAKO stockholders also approved the proposal to approve, on an advisory (non-binding) basis, specified compensation payable to the Company's named executive officers in connection with the merger.

Under the terms of the Merger Agreement, MAKO stockholders will receive $30 per share in cash at the closing of the merger. The parties anticipate that the transaction will close on December 17, 2013, and the parties intend that promptly thereafter MAKO will be delisted from Nasdaq.

About MAKO

MAKO Surgical Corp. is a medical device company that markets its RIO® Robotic-Arm Interactive Orthopedic system, joint specific applications for the knee and hip, and proprietary RESTORIS® implants for orthopedic procedures called MAKOplasty®. The RIO is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology, which enables precise, consistently reproducible bone resection for the accurate insertion and alignment of MAKO's RESTORIS implants. The MAKOplasty solution incorporates technologies enabled by an intellectual property portfolio including more than 300 U.S. and foreign, owned and licensed, patents and patent applications. Additional information can be found at www.makosurgical.com.

CONTACT: MAKO Surgical Corp.
         954-628-1706
         [e-mail]
         
         or
         
         Westwicke Partners
         Mark Klausner
         443-213-0500
         [e-mail]